Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

115.88 +0.83 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
64 65 Next >
3 Dirt Cheap Stocks to Buy Right Now
Bargain hunters should love these great stocks. 
Via The Motley Fool
Gilead Sciences Unusual Options Activity For September 20
 
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
 
Via Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
These two stocks have had their issues in recent years, but both look like reliable long-term bets. 
Via The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
 
Via Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
What the Options Market Tells Us About Gilead Sciences
 
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
 
Via Benzinga
Unveiling 10 Analyst Insights On Gilead Sciences
 
Via Benzinga
Why Gilead Sciences Stock Thrashed the Market Today
In drug development, solid performance in large-scale clinical trials is crucial. 
Via The Motley Fool
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by... 
Via Benzinga
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
The company is trying to get ahead of a patent expiration for one of its key HIV prevention drugs. 
Via Investor's Business Daily
Topics Intellectual Property
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
From Gilead Sciences, Inc.
Via Business Wire
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
 
Via Benzinga
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
From Gilead Sciences, Inc.
Via Business Wire
Four Stocks To Watch This Week - Monday, Sept 9
Inconsistent patchy behavior looks most likely in the very short term, but stocks still have decent potential in the medium term. Stay focused and be patient for the optimal setups near Key Levels. 
Via Talk Markets
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging technical signals. 
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
 
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
 
Via Benzinga
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
 
Via Benzinga
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. 
Via Investor's Business Daily
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs
Gilead Sciences exposes a major counterfeiting ring led by Peter Khaim, involving tampered HIV medications resold from New York pharmacies. The company seized over $750K in fake drugs, intensifying its... 
Via Benzinga
Topics Lawsuit
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
FDA grants accelerated approval to Gilead's Livdelzi (seladelpar) for primary biliary cholangitis, offering new treatment options for patients with inadequate response to standard therapy. Continued... 
Via Benzinga
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.